- Home
- BBNX vs EYPT Comparison
BBNX vs EYPT Comparison
Compare BBNX & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBNX
- EYPT
- Stock Information
- Founded
- BBNX 2015
- EYPT 1987
- Country
- BBNX United States
- EYPT United States
- Employees
- BBNX N/A
- EYPT N/A
- Industry
- BBNX Medical/Dental Instruments
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- BBNX Health Care
- EYPT Industrials
- Exchange
- BBNX Nasdaq
- EYPT Nasdaq
- Market Cap
- BBNX 740.7M
- EYPT 741.0M
- IPO Year
- BBNX 2025
- EYPT 2005
- Fundamental
- Price
- BBNX $26.41
- EYPT $13.35
- Analyst Decision
- BBNX Strong Buy
- EYPT Strong Buy
- Analyst Count
- BBNX 10
- EYPT 6
- Target Price
- BBNX $24.40
- EYPT $25.83
- AVG Volume (30 Days)
- BBNX 690.5K
- EYPT 783.3K
- Earning Date
- BBNX 11-06-2025
- EYPT 11-06-2025
- Dividend Yield
- BBNX N/A
- EYPT N/A
- EPS Growth
- BBNX N/A
- EYPT N/A
- EPS
- BBNX N/A
- EYPT N/A
- Revenue
- BBNX $69,830,000.00
- EYPT $51,898,000.00
- Revenue This Year
- BBNX $42.80
- EYPT N/A
- Revenue Next Year
- BBNX $34.58
- EYPT N/A
- P/E Ratio
- BBNX N/A
- EYPT N/A
- Revenue Growth
- BBNX 38911.17
- EYPT 2.99
- 52 Week Low
- BBNX $8.89
- EYPT $3.91
- 52 Week High
- BBNX $26.66
- EYPT $14.42
- Technical
- Relative Strength Index (RSI)
- BBNX 85.28
- EYPT 63.75
- Support Level
- BBNX $18.12
- EYPT $13.19
- Resistance Level
- BBNX $19.32
- EYPT $14.42
- Average True Range (ATR)
- BBNX 1.35
- EYPT 0.77
- MACD
- BBNX 0.75
- EYPT 0.11
- Stochastic Oscillator
- BBNX 97.43
- EYPT 66.14
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.